Fennec Pharmaceuticals Inc.
Market Cap
$295.33M
P/E Ratio
-30.63
EPS
$-0.35
Dividend Yield
0.00%
52-Week Range
$7.02 — $13.83
Volume
1
Avg Volume
493
Beta
0.81
P/E (TTM)
-30.63
Forward P/E
16.21
PEG Ratio
-0.76
P/S (TTM)
5.47
P/B (TTM)
-47.85
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
1.17%
ROA (TTM)
-0.14%
ROIC
—
Gross Margin
0.93%
Operating Margin
-0.12%
Net Margin
—
Debt/Equity
-4.03
Current Ratio
4.69
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+0.32%
EPS Growth (5Y)
+0.17%
Sales Growth (3Y)
+4.69%
Sales Growth (5Y)
+2.62%
EPS Est (This Year)
$0.66
EPS Est (Next Year)
$1.32
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$0.79
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
27.55M
Float
15.33M
Free Float %
55.65%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
TSX
IPO Date
2001-06-12
Employees
32
CEO
Jeffrey S. Hackman
Index Membership
—
Website
https://www.fennecpharma.com
Fennec Pharmaceuticals Inc. (FRX.TO) is a healthcare company in the biotechnology industry listed on the TSX. With a market capitalization of $295.33M, a P/E ratio of -30.63, FRX.TO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare FRX.TO against other stocks using dozens of fundamental and technical filters.
Fennec Pharmaceuticals Inc. (FRX.TO) has a trailing twelve-month (TTM) P/E ratio of -30.63. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Fennec Pharmaceuticals Inc. (FRX.TO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Fennec Pharmaceuticals Inc. (FRX.TO) has a market capitalization of $295.33 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.